Drug intelligence / Profile preview

iodo-willardiine

Development stage
Unknown
Modality
Small Molecules
01

Overview

Iodo-willardiine is a synthetic analog of the amino acid willardiine and acts as a highly potent and selective agonist for kainate receptors containing GluK1 (also known as GluR5) subunits. It exhibits high selectivity for these kainate receptor subtypes with an EC50 value of approximately 0.21 µM and shows minimal activity at AMPA receptors or other kainate receptor subunits such as GluK2, GluK6, or GluK7. Iodo-willardiine has been widely used in research to characterize the function of specific kainate receptor subtypes in neuronal signaling, apoptosis, necrosis, and neuropathic pain models. It is considered an experimental tool compound rather than a therapeutic drug[3][4][5].

Other names
(S)-(-)-5-IodowillardiineS-5-IodowillardiineS5-IodowillardiineS 5-Iodowillardiine(s)-5-Iodowillardiine5-Iodowillardiine5-(S)-Iodowillardiine(2S)-2-amino-3-(5-iodo-2,4-dioxopyrimidin-1-yl)propanoic acid2-amino-3-(5-Iodo–2,4-dioxo–3,4-dihydro–2H-pyrimidin–1–yl)propionic acid
02

Targets

GRIK1 (Glutamate ionotropic receptor kainate type subunit 1)

Beyond the preview

Go deeper on iodo-willardiine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on iodo-willardiine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call